The New England Journal of Medicine July 02, 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (CheckMate 067)

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.

Bottom Line

In patients with previously untreated advanced melanoma, treatment with the combination of nivolumab and ipilimumab, or with nivolumab alone, resulted in significantly longer progression-free survival than treatment with ipilimumab alone.

Key Findings

1. Median progression-free survival (PFS) was 11.5 months for the combination of nivolumab plus ipilimumab, compared with 6.9 months for nivolumab alone and 2.9 months for ipilimumab alone [2.1.2].

2. The hazard ratio for disease progression or death was 0.42 (99.5% CI, 0.31 to 0.57; P<0.001) for the combination versus ipilimumab.

3. The hazard ratio for nivolumab monotherapy versus ipilimumab was 0.57 (99.5% CI, 0.43 to 0.76; P<0.001).

4. Objective response rates (ORR) were highest in the combination group (57.6%), followed by the nivolumab group (43.7%) and the ipilimumab group (19.0%).

5. Grade 3 or 4 treatment-related adverse events occurred in 55.0% of patients receiving combination therapy, 16.3% of those receiving nivolumab alone, and 27.3% of those receiving ipilimumab alone.

Study Design

Design

Phase 3 RCT

Double-Blind

Sample

945

Patients

Duration

Minimum 9 mo

Median

Setting

Multinational

Population Patients with previously untreated, unresectable stage III or stage IV melanoma.

Intervention Nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for 4 doses followed by nivolumab (3 mg/kg) every 2 weeks; OR nivolumab (3 mg/kg) alone every 2 weeks.

Comparator Ipilimumab (3 mg/kg) alone every 3 weeks for 4 doses.

Outcome Progression-free survival (PFS) and overall survival (OS).

Study Limitations

• The trial was not powered to formally test for a statistically significant difference in efficacy between the nivolumab plus ipilimumab combination arm and the nivolumab monotherapy arm [2.2.3].

• The initial 2015 publication reported only on progression-free survival (PFS); overall survival (OS) data were immature at the time of the primary report.

• The remarkably high rate of Grade 3 or 4 adverse events (55.0%) in the combination arm led to a high treatment discontinuation rate.

• Predictive biomarkers remained inadequate; although PD-L1 expression was evaluated, patients with PD-L1 negative tumors still derived substantial benefit from the combination therapy.

Clinical Significance

CheckMate 067 fundamentally changed the treatment paradigm for advanced melanoma, establishing combined PD-1 and CTLA-4 blockade (or PD-1 blockade alone) as the new frontline standard of care. It definitively proved that dual immune checkpoint inhibition yields unprecedented, durable disease control, although this increased efficacy requires careful clinical management of substantially heightened immune-mediated toxicities.

Historical Context

Prior to 2011, metastatic melanoma was a devastating diagnosis with a median survival of under a year and few effective systemic options. The CTLA-4 inhibitor ipilimumab became the first therapy to demonstrate an overall survival benefit, followed rapidly by the development of PD-1 inhibitors like nivolumab. CheckMate 067 was the pivotal trial designed to test whether combining these two distinct immunotherapies could synergistically overcome tumor immune evasion compared to the newly established ipilimumab baseline.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How do the mechanisms of action of nivolumab and ipilimumab differ, and why is their combination biologically synergistic in treating advanced melanoma?

Key Response

Nivolumab blocks PD-1 to prevent T-cell exhaustion in the tumor microenvironment, while ipilimumab blocks CTLA-4 to enhance T-cell priming in the lymph nodes. Targeting both distinct phases of the immune response leads to a synergistic anti-tumor effect.

Resident

Given the results of CheckMate 067, how do the toxicity profiles of the combination therapy compare to monotherapy, and how should this influence your initial treatment discussion with a newly diagnosed advanced melanoma patient?

Key Response

Grade 3 or 4 treatment-related adverse events occurred in over 50 percent of the combination group versus around 20 percent in the nivolumab group. Residents must weigh the numerical survival benefit against the high risk of severe immune-related adverse events when counseling patients.

Fellow

CheckMate 067 stratified patients by PD-L1 expression. How should a patient's PD-L1 expression level influence your decision between prescribing nivolumab monotherapy versus the nivolumab and ipilimumab combination?

Key Response

Exploratory subgroup analysis suggested that patients with PD-L1 expression greater than or equal to 5 percent had similar progression-free survival with nivolumab alone compared to the combination. Fellows must critically weigh this biomarker utility against long-term survival data to potentially spare patients from combination toxicity.

Attending

The study was not formally powered to compare the nivolumab plus ipilimumab group directly against the nivolumab monotherapy group for overall survival. How do you communicate this statistical limitation to trainees when deciding whether the added toxicity of combination therapy is justified?

Key Response

Attendings must teach trainees to avoid over-interpreting numerical differences without formal statistical testing. The choice between combination and monotherapy often relies on clinical gestalt, patient fitness, and disease tempo rather than a definitively proven superiority of the combination over nivolumab alone.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

CheckMate 067 utilized a co-primary endpoint design of progression-free survival and overall survival. What are the statistical implications of using co-primary endpoints with three distinct treatment arms, and how does the testing strategy control for type I error?

Key Response

Using co-primary endpoints requires alpha-spending adjustments to maintain the overall family-wise error rate. Furthermore, having three arms requires a robust hierarchical testing structure, which is a critical methodological consideration for ensuring statistical validity without inflating false positive rates.

Journal Editor

In evaluating the long-term follow-up of CheckMate 067, a critical reviewer might flag the impact of subsequent therapies on overall survival. How does crossover and the administration of subsequent immune therapies confound the interpretation of the overall survival endpoint?

Key Response

A significant proportion of patients in the ipilimumab arm received anti-PD-1 therapy upon progression. An editor must assess how these subsequent treatments inflate the control arm's survival, potentially underestimating the true magnitude of benefit of the experimental arms.

Guideline Committee

Current NCCN and ESMO guidelines recommend both nivolumab monotherapy and combination therapy as category 1 options for first-line advanced melanoma based on CheckMate 067. What specific evidence thresholds must be met to definitively stratify which patients should receive combination versus monotherapy in future guidelines?

Key Response

Because CheckMate 067 lacked a formal statistical comparison between the combination and nivolumab monotherapy arms, guidelines leave the choice to the clinician. Updating guidelines to prefer one over the other requires non-inferiority or superiority trials directly comparing the two, ideally paired with validated predictive biomarkers.

Clinical Landscape

Noteworthy Related Trials

2010

MDX010-20 Trial

n = 676 · NEJM

Tested

Ipilimumab

Population

Patients with previously treated metastatic melanoma

Comparator

gp100 peptide vaccine

Endpoint

Overall survival

Key result: Ipilimumab improved overall survival in patients with previously treated metastatic melanoma, becoming the first therapy to demonstrate an overall survival benefit in this disease.

2015

KEYNOTE-006

n = 834 · NEJM

Tested

Pembrolizumab

Population

Patients with advanced melanoma

Comparator

Ipilimumab

Endpoint

Progression-free survival and Overall survival

Key result: Pembrolizumab significantly prolonged progression-free and overall survival and had less high-grade toxicity compared to ipilimumab.

2015

CheckMate 066

n = 418 · NEJM

Tested

Nivolumab

Population

Previously untreated BRAF wild-type advanced melanoma

Comparator

Dacarbazine

Endpoint

Overall survival

Key result: Nivolumab significantly improved overall survival compared to standard chemotherapy with a 1-year survival rate of 72.9% versus 42.1%.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis